2 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Delusions: new trials by email Literature Review of Delusions trials Research Report on Delusions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis ML-007C-MA, Placebo - Psychosis Associated With Alzheimer's Disease | Phase 2 | Recruiting | MapLight Therapeutics | 300 | 2025-08-15 | 2026-09-30 |
| ACP-204 in Adults With Alzheimer's Disease Psychosis ACP-204, Placebo - Alzheimer's Disease Psychosis | Phase 2 / Phase 3 | Recruiting | ACADIA Pharmaceuticals Inc. | 1074 | 2023-11-14 | 2026-10-19 |
Hallucinations (2) · Alzheimer Disease (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1) · Psychotic Disorders (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Tauopathies (1)
Behavior (2) · Behavioral Symptoms (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Perceptual Disorders (2) · Signs and Symptoms (2) · Nervous System Diseases (1)
ACADIA Pharmaceuticals Inc. (1) · MapLight Therapeutics (1)
Bulgaria (2) · Chile (2) · Czechia (2) · France (2) · Italy (2) · Serbia (2) · South Korea (2) · United States (2) · Argentina (1) · Brazil (1) · Canada (1) · Hungary (1) · Mexico (1) · Poland (1) · Portugal (1)